^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    HZ-R078

    i
    Other names: HZ-R078
    Associations

    News

    Trials
    Company:
    HealZen Therap
    Drug class:
    STAT3 protein degrader
    Related drugs:
    Associations

    News

    Trials
    over1year
    HZ-R078: A tumor-enriched STAT3 degrader for treating T-cell lymphoma in pre-clinical models (AACR 2023)
    HZ-R078 is a selective and potent STAT3 degrader which has tumor-enriched distribution character. The pre-clinical efficacy and safety study support its further development in clinical stage for T-cell lymphoma therapy.
    Preclinical
    |
    STAT3 (Signal Transducer And Activator Of Transcription 3) • STAT5B (Signal Transducer And Activator Of Transcription 5B) • STAT1 (Signal Transducer And Activator Of Transcription 1) • STAT6 (Signal transducer and activator of transcription 6) • STAT2 (Signal transducer and activator of transcription 2) • STAT4 (Signal Transducer And Activator Of Transcription 4)
    |
    HZ-R078